Drug Database
AN

antithrombin III

✓ Approved

GC Biopharma · SERPINC1 · Cell-based Therapies

What is antithrombin III?

antithrombin III is a cell-based therapies developed by GC Biopharma. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

CompanyGC Biopharma
Drug ClassCell-based Therapies
Molecular TargetSERPINC1
RouteInjectable (Others), Intravenous (IV)
StatusApproved
Sources: ClinicalTrials.gov, GC Biopharma

Mechanism of Action

Molecular Targets

antithrombin III acts on 1 molecular target:

SERPINC1serpin family C member 1 (ATIII, AT3D)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

antithrombin III is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Congenital, familial and genetic disordersAntithrombin III deficiency✓ Approved

Related Research Articles

PubMedOrganic letters2026-08-30

Rh(III)-Catalyzed Multicomponent Formal [4 + 2+1]/[4 + 1] Annulation for the Synthesis of Benzo[d]pyrazolo[1,5-a]azepin-4-ones.

Luo Qin Q, Wei Meng-Zhen MZ, Wang Yi-Ting YT, Xie Zhi-Bo ZB et al.

A Rh(III)-catalyzed three-component cascade cyclization has been developed for the efficient synthesis of highly functionalized benzo[d]pyrazolo[1,5-a]azepin-4-ones (BPAPOs) from a sulfoxonium ylide, a vinyl diazo ester, and excess vinylene carbonate. The reaction proceeds through a formal [4 + 2+1]/[4 + 1] cyclization cascade, rapidly constructing the tricyclic BPAPO framework and forming five new chemical bonds in a one-pot process. Notably, the two stereocenters in the target molecules can be controlled through temperature-dependent diastereoselectivity: Temperature-controlled diastereoselectivity enables the selective formation of diastereomer 4 at 100 °C and diastereomer 5 at 70 °C, both with high dr values. Their relative configurations were confirmed by single-crystal X-ray diffraction. The method features broad substrate scope and good functional-group tolerance, providing efficient access to diverse tricyclic scaffolds for biological and medicinal chemistry.

PMID 42669078
Read full article →
PubMedEuropace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology2026-08-30

Population reach and participation rate in opportunistic vs. systematic atrial fibrillation screening: STROKESTOP III.

Khan Mashroor M, Skröder Sofia S, Ingre Michael M, Carlstedt Fredrik F et al.

Population-based screening for atrial fibrillation (AF) should be considered in elderly individuals to enable AF detection. However, participation in systematic screening programmes is often suboptimal. STROKESTOP III evaluated whether opportunistic screening could improve participation compared with systematic screening. STROKESTOP III is a cluster-randomized trial including individuals aged 75-76 years from 16 primary care centres in Region Värmland, Sweden. Centres were randomized to systematic screening, using mailed invitations, or opportunistic screening, using invitations during visits.In the systematic arm, 1312 individuals were eligible and invited, of whom 607 participated (46.3%). In the opportunistic arm, 1390 individuals attended participating primary care centres and were potentially eligible for invitation. However, 641 individuals (46.1%) were not assessed for eligibility. Among the 749 assessed individuals, 609 were eligible and 374 participated.Participation among invited eligible individuals was significantly higher with opportunistic than systematic screening (374/609, 61.4% vs. 607/1,312, 46.3%; P < 0.005). However, overall reach was lower in the opportunistic arm because of incomplete assessment for invitation (374/1,479, 25.3% vs. 607/1,437, 42.2%; P < 0.005). Participants in the opportunistic arm had a higher cardiovascular risk burden, including more hypertension, diabetes, and a higher CHA2DS2-VASc-score (3.99 vs. 3.60; P < 0.005). Exclusion rates were higher (18.7% vs. 8.7%; P < 0.005), mainly due to previously diagnosed AF and cognitive impairment. Opportunistic screening increased participation among invited individuals and identified a higher-risk population, but its overall population reach was limited by incomplete eligibility assessment. Combining opportunistic and systematic strategies may optimize reach and participation in AF screening programmes.

PMID 42669050
Read full article →
PubMedEnvironmental geochemistry and health2026-08-30

Hydrogeochemical controls on chromium speciation and potential human health risks in surface waters of an ultramafic mining watershed.

Kutlu Banu B, Baydar Tarık T, Yıldırım Vesile V, Konurhan Zekeriya Z

Accurate assessment of chromium contamination in mining-influenced watersheds requires distinguishing between the environmentally contrasting Cr(III) and Cr(VI) species, yet environmental monitoring and risk assessments still rely predominantly on total chromium concentrations. This study evaluated whether chromium speciation provides additional information beyond operational total chromium for assessing chromium occurrence and potential human health risks in an ultramafic, mining-influenced watershed. Surface-water samples were collected from 28 sampling stations across the Pülümür and Ovacık regions of the Eastern Anatolia Basin (Türkiye) between March 2025 and February 2026. Chromium speciation was determined using species-specific UV-Visible spectrophotometric methods and integrated with hydrochemical characterization, multivariate statistical analyses, mineralogical investigations (XRD, SEM-EDS, and FTIR), and deterministic and empirical-bootstrap human health risk assessments. Operational total chromium, defined as the sum of separately measured Cr(III) and Cr(VI), ranged from below the detection limit to 578.13 µg L-1. For contextual screening, this calculated value exceeded World Health Organization (WHO) drinking-water guideline for total chromium at 14 stations; however, it was not an independently measured total-Cr concentration. The highest Cr(VI) concentration occurred at a localized hotspot, whereas Cr(III) predominated throughout most of the watershed. Nevertheless, Cr(VI)-based screening thresholds were exceeded at multiple stations under the assumed untreated drinking-water ingestion scenario, indicating that operational total chromium alone did not consistently identify the spatial distribution of Cr(VI)-related potential risk. Screening-level hazard quotient (HQ) estimates were higher for children than for adults; however, direct untreated consumption of the sampled surface waters was not verified. Mining-influenced stations generally exhibited higher chromium concentrations, although the relative contributions of geogenic weathering and mining-related mobilization could not be quantitatively apportioned. Overall, chromium speciation provided additional environmentally and toxicologically relevant information beyond operational total chromium for evaluating chromium mobility and screening-level potential human health risks in this ultramafic watershed.

PMID 42668290
Read full article →
PubMedJournal of molecular histology2026-08-30

Early effects of X-ray irradiation on rat incisor periodontal ligament morphology and MMP-2 expression.

Fischborn Amanda Regina AR, Sartor Letícia L, Omar Nadia Fayez NF, Gomes Jose Rosa JR

Radiotherapy is an effective treatment for head and neck cancer; however, it also induces alterations in healthy oral tissues. Although late radiation-induced damage has been extensively investigated, the early progression of morphological and extracellular matrix changes in the periodontal ligament (PDL) remains poorly understood. This study investigated early radiation-induced changes in collagen organisation, the type I-to-type III collagen ratio, and matrix metalloproteinase-2 (MMP-2) expression in the lingual PDL of rat incisors. Adult Wistar rats were allocated to four irradiated groups (n = 5 per group) and exposed to a single 15 Gy X-ray dose directed to the head. Animals were euthanized at 4, 9, 14, or 25 days after irradiation. A non-irradiated control group was euthanized on day 4. Left hemimandibles were fixed, decalcified, embedded in paraffin, and sectioned. Histological analyses were performed using hematoxylin and eosin, Masson's trichrome, and Picrosirius Red staining under polarized light. MMP-2 expression was evaluated by immunohistochemistry and quantified by grayscale pixel intensity analysis. Irradiation induced progressive alterations in the lingual periodontal ligament. Fibroblast nuclei exhibited morphological features consistent with cellular injury beginning on day 4, with increasing changes at subsequent time points. These changes were accompanied by progressive disorganisation of collagen bundles, increased interfibrillar spaces, and loss of normal extracellular matrix architecture. Picrosirius Red analysis demonstrated a reduction in the type I-to-type III collagen ratio on days 4, 9, and 14 after irradiation, supporting the morphological changes observed with H.E and Masson's trichrome staining. MMP-2 expression increased significantly on day 4, reached its highest level on day 9, and then progressively decreased on days 14 and 25. A single dose of X-ray irradiation induces early morphological and extracellular matrix alterations in the rat incisor periodontal ligament. The temporal association between increased MMP-2 expression, collagen fibre disorganisation, and a decreased type I-to-type III collagen ratio suggests that MMP-2 is associated with the early extracellular matrix remodelling observed on days 4 and 9 after irradiation. The subsequent decline in MMP-2 expression was accompanied by an apparent partial restoration of collagen fibre organisation on days 14 and 25.

PMID 42669096
Read full article →
PubMedEuropean journal of internal medicine2026-08-30

Phenotypic clustering and ABC pathway adherence in patients with atrial fibrillation at high risk of bleeding and stroke: Insights from three global registries.

Askarinejad Amir A, Bucci Tommaso T, Tartaglia Enrico E, Rigutini Andrea Galeazzo AG et al.

Patients with atrial fibrillation (AF) who are at increased risk of both thrombotic and haemorrhagic events represent a heterogeneous and broad clinical entity, characterized by the presence of several Janus-faced risk factors. We aimed to identify clinical phenotypes and assess the association of ABC pathway adherence with one-year outcomes in patients with AF at high risk of both stroke and bleeding. AF patients who had HAS-BLED score ≥3 and CHA2DS2-VASc score ≥2 were included. Hierarchical clustering was applied to identify phenotypic subgroups. We assessed the impact on net adverse clinical event (NACE) of adherence to the integrated care based on the Atrial fibrillation Better Care (ABC) pathway. A total of 2,535 patients (mean age 75.4 ± 7.8 years; 58.3% male) were enrolled. Cluster I had the highest rates of prior thromboembolic and haemorrhagic events with the lowest comorbidity burden; Cluster II comprised the oldest patients with the highest prevalence of dyslipidaemia, heart failure, and peripheral artery disease; Cluster III was the youngest with the highest BMI and alcohol use. Cluster II (aOR 1.93, 95% CI 1.37-2.78), and Cluster III (aOR 1.65, 95% CI 1.10-2.50) were associated with a higher risk of all-cause death compared to Cluster I. Among patients with available ABC pathway data, adherence was associated with lower odds of 1-year MACE (OR 0.39, 95% CI 0.15-0.82). Three distinct phenotypic clusters were identified, each with heterogeneous clinical characteristics and outcomes, underscoring the need for more individualised, phenotype-informed management strategies in this complex patient population.

PMID 42669578
Read full article →
PubMedPostgraduate medicine2026-08-30

Waist circumference provides improved cardiometabolic discrimination compared with body mass index in psoriatic disease: discrimination and reclassification analyses.

Queiro Rubén R, Pardo Estefanía E, Loredo Marta M, Burger Stefanie S et al.

Patients with psoriatic disease present a distinctive metabolic phenotype, yet the optimal anthropometric marker to capture cardiometabolic risk remains unclear. We evaluated whether waist circumference provides superior cardiometabolic discrimination and reclassification compared with BMI in psoriatic disease. In this cross-sectional study, we assessed consecutive patients with psoriasis and/or psoriatic arthritis (n = 572). The primary outcome was clustered cardiometabolic burden (≥2 predefined cardiometabolic abnormalities). Waist circumference and BMI were compared using principal component analysis (PCA), ROC curves, Youden-derived sex-specific thresholds, and both categorical and continuous reclassification metrics (NRI and IDI), overall and stratified by sex. Additional sensitivity analyses used standard metabolic cutoffs (ATP III/IDF). Waist circumference and BMI showed the highest loadings on the first principal component representing the cardiometabolic axis, with a slightly higher contribution from waist circumference (loading 0.864 vs 0.826). Waist circumference showed modest but statistically significant improvement in discrimination compared with BMI for clustered cardiometabolic abnormalities (AUC 0.78 vs 0.73 for ≥2 factors, DeLong p = 0.003; AUC 0.78 vs 0.71 for ≥3 factors, DeLong p < 0.001). Waist circumference-derived thresholds provided incremental risk stratification beyond BMI, with consistent improvements in reclassification metrics across cardiometabolic burden definitions. Youden-derived thresholds (100 cm in men and 99 cm in women) showed better balance between sensitivity and specificity than ATP III and IDF criteria, while maintaining clinically relevant likelihood ratios. Sensitivity analyses incorporating waist-to-height ratio showed similar findings without additional benefit over waist circumference alone. Waist circumference provided consistently better overall cardiometabolic discrimination than BMI and may represent a more informative anthropometric marker for cardiometabolic risk assessment in psoriatic disease.

PMID 42669569
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about antithrombin III